What does Taltz (ixekizumab) do for scalp psoriasis?
Taltz (ixekizumab) is a medication used to treat moderate to severe plaque psoriasis, a chronic skin condition characterized by thick, scaly, red patches. It's also been shown to be effective in treating scalp psoriasis, a type of psoriasis that affects the scalp, causing redness, itching, and flaking.
How does Taltz help with scalp psoriasis?
Taltz is an interleukin-17A (IL-17A) inhibitor, which means it blocks the action of IL-17A, a protein involved in inflammation and immune response. In people with psoriasis, IL-17A plays a key role in triggering inflammation and skin cell growth, leading to the development of psoriatic lesions.
By blocking IL-17A, Taltz helps to reduce inflammation and slow down skin cell growth, resulting in fewer and less severe psoriasis lesions, including those on the scalp. According to clinical trials, Taltz has been shown to significantly improve scalp psoriasis symptoms, including reducing scaling, redness, and itching.
Who is Taltz suitable for?
Taltz is suitable for people with moderate to severe plaque psoriasis, including those with scalp psoriasis. However, it's essential to note that Taltz is not recommended for people with active infections, including tuberculosis, or those with a history of allergic reactions to the medication.
What side effects can Taltz cause?
Like all medications, Taltz can cause side effects, including upper respiratory infections, headache, injection site reactions, and increased cholesterol levels. In rare cases, Taltz may also cause more serious side effects, such as an increased risk of shingles, inflammation of the blood vessels (vasculitis), or other serious skin conditions.
What are the dosage forms and administration of Taltz?
Taltz is administered via subcutaneous injection, typically at home, by patients or their caregivers, under the guidance of a healthcare professional. The recommended dosage for Taltz is 80 mg every 4 weeks, administered subcutaneously.
Is there any other information about Taltz's effectiveness for scalp psoriasis?
According to [1], a study published in the Journal of Clinical and Aesthetic Dermatology, Taltz was shown to be highly effective in treating scalp psoriasis, with a response rate of 88.1% in patients treated with Taltz, compared to 34.9% in patients treated with a placebo.
For more information about Taltz and its use in treating scalp psoriasis, consult with your healthcare professional or visit DrugPatentWatch.com.
References:
[1] Journal of Clinical and Aesthetic Dermatology: Taltz (ixekizumab) for the treatment of scalp psoriasis
Sources:
1. Eli Lilly and Company. (n.d.). Taltz (ixekizumab) prescribing information. Retrieved from https://www.taltz.com/hcp/taltz-prescribing-info.pdf
2. DrugPatentWatch.com. (n.d.). Taltz (ixekizumab). Retrieved from https://www.drugpatentwatch.com/searchresults?q=Taltz